Login to Your Account

Financings Roundup

Third Tranche Adds $23M to PhaseBio's Series B Round

By Catherine Shaffer
Staff Writer

Wednesday, June 6, 2012
A third tranche of $23 million brings PhaseBio Pharmaceuticals Inc.'s Series B financing total to $48.4 million. The disbursement was triggered by completion of a Phase I/IIa trial of Glymera in Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription